期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 5, 期 1, 页码 195-203出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.5.1.195
关键词
choroidal neovascularisation; macular degeneration; ocular histoplasmosis; pathologic myopia; photodynamic therapy; verteporfin; visudyne
This article reviews the pharmacotherapeutics of verteporfin (Visudyne(R), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials with verteporfin to treat subfoveal choroidal neovascularisation in age-related macular degeneration, ocular histoplasmosis syndrome and pathologic myopia. In addition, the safety profile and side effects of verteporfin are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据